World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cance... (m our Fresh From Our Growers(R) collec...)

(Date:5/13/2008)...., May 13 /- Dried blood spots are em...serum collection and transport,for blood tests. In...l of,Diabetes Science and Technology (2008; 2(2):2...e use of dried blood spots is a "powerful tool", f...developing countries with,limited health budgets.,...

(Date:5/13/2008)... and BARCELONA, Spain, May 13 /PRNewswire-FirstCal...today welcomed two-year results,from the SPIRIT II...roven,long-term safety and efficacy of the market-...oronary Stent System and reinforce the growing bod... V (PROMUS(TM)),Everolimus-Eluting Coronary Stent ...

(Date:5/13/2008)...ted with XIENCE V in SPIRIT III Trial Experience B... Stent Thrombosis than Patients ... 13 /- Long-term data,prese...trial, Abbott,s U.S.,pivotal trial studying the XI...m, demonstrated that XIENCE V continues to deliver...

(Date:5/13/2008)...LIS, France, May 13 /- NicO...& Co., Inc. has initiated the,first in a series of...ertensive patients, under the companies, collabora...g antihypertensive agents using NicOx,proprietary...elected from,the companies, joint research program...

Breaking Medicine Technology:Blood Spot Technology at ZRT Highlighted in March Issue of Journal of Diabetes Science & Technology - A Convenient Alternative to Serum Testing for Health Screening 2 SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents 2 SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents 3 SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents 4 XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years 2 XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years 3 XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years 4 XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years 5 NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc. 2 NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc. 3 African medical research and training receives Wellcome boost 16519 1 African medical research and training receives Wellcome boost 16519 2 SAPPHIRE trial shows long term benefit of carotid stenting as alternative to surgery 16517 1 SAPPHIRE trial shows long term benefit of carotid stenting as alternative to surgery 16517 2 SAPPHIRE trial shows long term benefit of carotid stenting as alternative to surgery 16517 3 Study Showed Minimally Invasive Surgery Reduced Risk of Hospital Acquired Infections Compared to Open Surgery 16516 1 Study Showed Minimally Invasive Surgery Reduced Risk of Hospital Acquired Infections Compared to Open Surgery 16516 2 Study Showed Minimally Invasive Surgery Reduced Risk of Hospital Acquired Infections Compared to Open Surgery 16516 3 Rejuvasun 28TM 29 With Omnilux 28TM 29 3A Industry First to Feature FDA Cleared Clinically Proven Light Therapy Technology 16514 1 Rejuvasun 28TM 29 With Omnilux 28TM 29 3A Industry First to Feature FDA Cleared Clinically Proven Light Therapy Technology 16514 2 Rejuvasun 28TM 29 With Omnilux 28TM 29 3A Industry First to Feature FDA Cleared Clinically Proven Light Therapy Technology 16514 3

[0] Blood Spot Technology at ZRT Highlighted in March Issue of Journal of Diabetes Science & Technology - A Convenient Alternative to Serum Testing for Health Screening [0] SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents [0] XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years [0] NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.

...RE)--Jun 18, 2007 - Advanced Viral,Research Corp. ...company, announced today that preliminary findings...ow topical treatment with AVR118,appears to have c...ess associated with surgical incisions or dermatol...ological study is evaluating the,activity of a top...

...Influenza Conference , HIGH WYCOMBE, UK 18th June ...ing how a new flu vaccine has the potential,to pro...andemic and,annual, was presented today by PepTcel...a VI (Options) Conference, in Toronto,Canada. , T...n the,European Journal of Immunology, showed how m...

Other Medicine Technology:Advanced Viral Research Corp. Announces Positive Preliminary,Findings from Ongoing Phase II Dermatological Study 2 New Flu Vaccine from PepTcell Could Provide Immunity Against All,Strains of Influenza Virus 2 New Flu Vaccine from PepTcell Could Provide Immunity Against All,Strains of Influenza Virus 3 New Flu Vaccine from PepTcell Could Provide Immunity Against All,Strains of Influenza Virus 4 New Flu Vaccine from PepTcell Could Provide Immunity Against All,Strains of Influenza Virus 5

Advanced Viral Research Corp. Announces Positive Preliminary,Findings from Ongoing Phase II Dermatological Study New Flu Vaccine from PepTcell Could Provide Immunity Against All,Strains of Influenza Virus

(Date:5/13/2008)...-- United American Healthcare,Corporation (Nasdaq:...nagement services to a full-service managed care o...l results for its third fiscal quarter,ended March... million for the third fiscal,quarter ended March ...or,the third quarter of the prior fiscal year. The...

(Date:5/13/2008)...re-FirstCall/ -- IRIDEX,Corporation (Nasdaq: IRIX...quarter of 2008 ended March 29, 2008., Revenue fo...8.7%,decrease from the $12.6 million reported for ...was $0.9 million or $0.10 per diluted share for th...f $4.9 million or $0.61 per,diluted share in the f...

(Date:5/13/2008)... Ongoing; Company Prepares for, Potential 2008 Lau...llion in Quarter, G...iddleBrook,Pharmaceuticals, Inc. (Nasdaq: MBRK ),...d commercializing novel anti-infective products, t...or the quarter ended March 31,2008., MiddleBrook...

(Date:5/13/2008)... the poor from improving, study finds , ,...of care at hospitals that treat poor and underserv... lagging well behind hospitals that do not serve t...tals, which rely on state and federal funding from... to improve the quality of care at the same rate t...

[0] United American Healthcare Corporation Announces Fiscal 2008 Third Quarter Results [0] IRIDEX Reports First Quarter 2008 Financial Results [0] MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results [0] Quality Lags at Safety-Net Hospitals

...ed out over 6,000 chlamydia testing kits across Lo... tackling the silent sex disease. It is part of t... last year revealed as many as one in nine of 16-2...trial was launched in November to encourage young ...

... planning for reduction of waiting time spent by p...ent is planning to reduce the non-emergency surger...ission to NHS. Government is hoping the project wi...ait for long time for initial appointment with the...

... Punjab state are using decoy customers to trap do...rn babies which // has been outlawed. The State’...00 males. Officials said the decoy customers wou... diagnostic centers indulging in illegal sex deter...

...e Anglo-Swedish Company has come out with the resu...n the treatment of // both maniac behaviour and...r disorders. He has asked US to consider his drug... and depression symptoms related to bipolar disord...

Other Medicine News:

Huge demand for high street chlamydia tests U.K. Government to reduce waiting time of patients for non-emergency surgery Punjab Government To Clamp Down On Sex Determination Tests Seroquel to Treat Depression In Case Of Bipolar Disorder

Tegagel hydrogel wound filler and Tegagel hydrogel wound filler with gauze are amorphous hydrogel dressings specially formulated to help provide a moist environment that has been shown to enhance wou

... physician preference card system as well as a per...ply management requirements of the surgical servic... with a broad array of inventory management capabi...suite supply and charge capture workflow. Regardle...

...rade; External Vacuum Therapy System restores sexu...ive and low cost vacuum therapy, coupled with its ..., makes it the ideal therapy for treating erectile... System causes penile rigidity that can be maintai...

Easy to Use manual vacuum system features a pumping mechanism that can be operated with one hand.

Medicine Products:

3M™ Tegagel™ Hydrogel Wound Filler OptiFlex SS ErecAid® Esteem™ External Vacuum Therapy System Osbon ErecAid Vacuum Therapy System - Manual

World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cance...(m our Fresh From Our Growers(R) collec...),Health